Emtricitabine 200mg / Tenofovir disoproxil 245mg tablets
NHS hospitals in England used £241,311,354 of indicative cost of Emtricitabine 200mg / Tenofovir disoproxil 245mg tablets in the 12 months to April 2026, about 0.9% of all hospital medicines spend. That is down 5.6% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Emtricitabine 200mg / Tenofovir disoproxil 245mg tablets: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to April 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Emtricitabine 200mg / Tenofovir disoproxil 245mg tablets most
By indicative cost over the 12 months to April 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| Chelsea & Westminster Hospital Nhs Ft | £76,979,017 |
| Manchester University Nhs Ft | £18,335,824 |
| Guy's & St Thomas' Nhs Foundation Trust | £11,366,722 |
| Western Sussex Hospitals Nhs Found Trust | £10,162,906 |
| Barts Health Nhs Trust | £9,239,881 |
| Univ Hpl B/Ham Nhs Foundation Trust | £8,716,162 |
| Imperial College Healthcare Nhs Trust | £6,363,796 |
| Aintree University Hospital Nhs Ft | £6,196,531 |
| Lewisham And Greenwich Nhs Trust | £4,829,295 |
| London North West Healthcare Nhs Trust | £4,201,179 |
The primary-care picture
Emtricitabine is also dispensed in the community. See the national primary-care prescribing volume, cost and trend on the Emtricitabine medicine page.